Search results
Results from the WOW.Com Content Network
Marginal zone lymphoma (MZL) is a group of indolent (slow growing) NHL B-cell lymphomas, which account for approximately eight percent of all NHL cases. The average age at diagnosis is 60 years, and it is slightly more common in women than in men.
The Understanding Lymphoma fact sheet series is published by the Lymphoma Research Foundation (LRF ) for the purpose of informing and educating readers. Facts and Facts and statistics were obtained using published information, including d ata from the Surveillance, Epidemiology, and End Results (SEER) Progr am.
Marginal zone lymphomas (MZLs) are a group of indolent (slow-growing) B-cell non-Hodgkin lymphomas (NHLs), beginning in a part of lymph tissue called the marginal zone, which account for approximately 5 to 10 percent of all NHL cases.
MZL is the third most common indolent lymphoma and accounts for approximately 5 to 10% of all NHLs. The number of new cases of MZL increases with age, but the average age at diagnosis depends on the type of MZL (see below). Understanding Lymphoma and Chronic Lymphocytic Leukemia (CLL) Marginal Zone Lymphoma
Treatment selection for a patient with Marginal Zone Lymphoma (MZL) depends on the type, the stage and location of the disease, the patient’s age and overall health, and any lymphoma-related signs or symptoms.
To learn about treatments under investigation for Marginal Zone Lymphoma, download the Marginal Zone Lymphoma Fact Sheet. Download the Clinical Trials Fact Sheet.
Get lymphoma and CLL resources and updates. Sign Up The Lymphoma Research Foundation’s mission is to realize the promise of science to eradicate lymphoma and serve the community touched by this disease.
Marginal Zone Lymphoma: Long-term Survivorship. Patients in remission should have regular visits with a physician who is familiar with their medical history and the treatments they have received.
• Lymphoma is the most common type of blood cancer and causes lymphocytes, a kind of white blood cell, to grow and multiply uncontrollably 1,2 • Around 90% of lymphomas are categorized as non-Hodgkin’s lymphoma (NHL) 1
In April of 2019, the Lymphoma Research Foundation (LRF) gathered international experts in the field of marginal zone lymphoma (MZL) in New York City for the inaugural International Scientific Workshop on Marginal Zone Lymphoma. MZL is an uncommon non-Hodgkin lymphoma with a typically indolent clinical course. The management of